fbpx

molecules of the month

GS-9876 (lanraplenib)

SYK-selective kinase inhibitor

oral, completed Ph. I in HV

from optimization of prior candidate

ACS Med. Chem. Lett. Feb. 12, 2020

Gilead Sciences, Seattle, WA

GS-9876 (lanraplenib)
1 min read

GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: